Blood Res.  2022 Sep;57(3):223-228. 10.5045/br.2022.2022014.

Endothelial nitric oxide synthase Glu298Asp gene polymorphism in the cases of idiopathic thrombocytopenic purpura

• Akarsu S
• Arslan FN
• Erol D

• KMID: 2533250
• DOI: http://doi.org/10.5045/br.2022.2022014

Abstract

Background
Nitric oxide (NO) can induce apoptosis in megakaryocytes. Stimulatory function of NO on platelet production may be important in the pathophysiology of idiopathic thrombocytopenic purpura (ITP). NO is produced by three isoforms of NO synthase (NOS). The endothelial nitric oxide synthase (eNOS) isoform has been detected in platelets. Polymorphism of the eNOS gene, which supplies NO synthesis, changes the functions of this enzyme. In this study, the role of eNOS Glu298Asp gene polymorphism in etiopathogenesis, its course, and treatment of ITP was investigated.
Methods
Sixty-six patients [51 newly diagnosed ITP (ND-ITP), 15 chronic ITP (CH-ITP), and 60 healthy controls (HC)] were enrolled in this study.
Results
In all patients, the frequency of the GT genotype was 48.5%. The frequency of the GG genotype was determined to be 40.9% and the TT genotype was 10.6%. The most common allele in all patients was the G allele. eNOS Glu298Asp gene polymorphism might be a risk factor in the etiopathogenesis of ITP. Patients with the GG genotype were thought to have a high intention for CH-ITP. Patients with the GG genotype responded effectively to medical treatment using IVIG therapy. The presence of the G allele was observed to have a positive effect on the medical treatment of patients with CH-ITP, whereas the T allele exhibited a negative effect.
Conclusion
In the present study, a significant correlation was found between ITP and eNOS Glu298Asp gene polymorphism. This correlation suggested that eNOS Glu298Asp gene polymorphism might be a risk factor in the ethiopathogenesis of ITP.

Keyword

Idiopathic thrombocytopenic purpura (ITP); Endothelial nitric oxide synthase (eNOS); Glu298Asp gene; Polymorphism

Figure

• 

  Fig. 1 eNOS gene polymorphisms (exon 7: G894T polymorphism= Glu298Asp polymorphism) [15].

• 

  Fig. 2 Agarose gel electrophoresis and schematic view of PCR products cut by Ban II enzyme of eNOS gene Glu298Asp polymorphism. Case 1 and 2: GG genotype, Case 3 and 4: GT genotype, Case 5 and 6: TT genotype. T allele 248 base couple (bc), G allele 163 and 85 bc. M: 100 bc DNA dimension marker.

• 

  Fig. 3 Dispersion of eNOS Glu298Asp G/T genotype in the patient and control groups. 1a–4a=P<0.05, 1b–4b=P<0.05, 3c–4c=P<0.05, 2a–4a=P<0.05, 2b–4b=P<0.05, 3a–4a=P<0.05, 3b–4b=P<0.05.

Reference

1. Wentworth P Jr, Jones LH, Wentworth AD, et al. 2001; Antibody catalysis of the oxidation of water. Science. 293:1806–11. DOI: 10.1126/science.1062722. PMID: 11546867. PMCID: PMC122400.

2. Jin CQ, Dong HX, Cheng PP, Zhou JW, Zheng BY, Liu F. 2013; Antioxidant status and oxidative stress in patients with chronic ITP. Scand J Immunol. 77:482–7. DOI: 10.1111/sji.12048. PMID: 23551069.

3. Cura M, Koç A, Aksoy N, Özdemir ZC. 2016; Effect of short-term, high-dose methylprednisolone on oxidative stress in children with acute immune thrombocytopenia. Blood Res. 51:261–7. DOI: 10.5045/br.2016.51.4.261. PMID: 28090489. PMCID: PMC5234230.

4. Bivalacqua TJ, Champion HC, Hellstrom WJ. 2002; Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie's disease. Int J Impot Res. 14:345–52. DOI: 10.1038/sj.ijir.3900872. PMID: 12454685.

5. Thachil J. 2009; Nitric oxide in immune thrombocytopenic purpura. Hematology. 14:59–62. DOI: 10.1179/102453309X385151. PMID: 19154666.

6. Hoffmann A, Gloe T, Pohl U. 2001; Hypoxia-induced upregulation of eNOS gene expression is redox-sensitive: a comparison between hypoxia and inhibitors of cell metabolism. J Cell Physiol. 188:33–44. DOI: 10.1002/jcp.1092. PMID: 11382920.

7. Polat G, Tamer L, Tanriverdi K, Gürkan E, Baslamisli F, Atik U. 2002; Levels of malondialdehyde, glutathione and ascorbic acid in idiopathic thrombocytopaenic purpura. East Afr Med J. 79:446–9. DOI: 10.4314/eamj.v79i8.8833. PMID: 12638848.

8. Mineo C. 2013; Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis. Curr Rheumatol Rep. 15:324. DOI: 10.1007/s11926-013-0324-4. PMID: 23519891. PMCID: PMC3625922.

9. Förstermann U, Sessa WC. 2012; Nitric oxide synthases: regulation and function. Eur Heart J. 33:829–37. 837a–d. DOI: 10.1093/eurheartj/ehr304. PMID: 21890489. PMCID: PMC3345541.

10. Battinelli E, Loscalzo J. 2000; Nitric oxide induces apoptosis in megakaryocytic cell lines. Blood. 95:3451–9. DOI: 10.1182/blood.V95.11.3451. PMID: 10828028.

11. Battinelli E, Willoughby SR, Foxall T, Valeri CR, Loscalzo J. 2001; Induction of platelet formation from megakaryocytoid cells by nitric oxide. Proc Natl Acad Sci U S A. 98:14458–63. DOI: 10.1073/pnas.241427398. PMID: 11734646. PMCID: PMC64703.

12. Rodeghiero F, Stasi R, Gernsheimer T, et al. 2009; Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 113:2386–93. DOI: 10.1182/blood-2008-07-162503. PMID: 19005182.

13. Provan D, Stasi R, Newland AC, et al. 2010; International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 115:168–86. DOI: 10.1182/blood-2009-06-225565. PMID: 19846889. PMCID: PMC6880896.

14. Thude H, Gruhn B, Werner U, et al. 2004; Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis. Acta Haematol. 111:221–4. DOI: 10.1159/000077570. PMID: 15153715.

15. Garg UC, Hassid A. 1989; Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1774–7. DOI: 10.1172/JCI114081. PMID: 2540223. PMCID: PMC303890.

16. Alderton WK, Cooper CE, Knowles RG. 2001; Nitric oxide synthases: structure, function and inhibition. Biochem J. 357:593–615. DOI: 10.1042/bj3570593. PMID: 11463332. PMCID: PMC1221991.

17. Radomski MW, Palmer RM, Moncada S. 1987; Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 2:1057–8. DOI: 10.1016/S0140-6736(87)91481-4. PMID: 2889967.

18. Kolb H, Kolb-Bachofen V. 1992; Nitric oxide: a pathogenetic factor in autoimmunity. Immunol Today. 13:157–60. DOI: 10.1016/0167-5699(92)90118-Q. PMID: 1379434.

19. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. 2000; Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A. 97:2832–5. DOI: 10.1073/pnas.97.6.2832. PMID: 10717002. PMCID: PMC16015.

20. Veldman BA, Spiering W, Doevendans PA, et al. 2002; The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens. 20:2023–7. DOI: 10.1097/00004872-200210000-00022. PMID: 12359981.

21. Yoon Y, Song J, Hong SH, Kim JQ. 2000; Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin Chem. 46:1626–30. DOI: 10.1093/clinchem/46.10.1626. PMID: 11017941.

22. Serrano NC, Páez C, Correa PA, Anaya JM. 2004; Endothelial nitric oxide synthase gene polymorphism is associated with systemic lupus erythematosus. J Rheumatol. 31:2163–8. PMID: 15517628.

23. Kim JU, Chang HK, Lee SS, et al. 2003; Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease and rheumatic diseases with vasculitis. Ann Rheum Dis. 62:1083–7. DOI: 10.1136/ard.62.11.1083. PMID: 14583572. PMCID: PMC1754357.

24. Oe Y, Ko M, Fushima T, et al. 2018; Hepatic dysfunction and throm-bocytopenia induced by excess sFlt1 in mice lacking endothelial nitric oxide synthase. Sci Rep. 8:102. DOI: 10.1038/s41598-017-18260-7. PMID: 29311569. PMCID: PMC5758763.